10X Genomics Inc
TXG
View Detailed Chart
19.290USD
-0.700-3.50%
Close 01/08, 16:00（ET）Quotes delayed by 15 min
2.44BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.50%
5 Days
+18.27%
1 Month
+10.42%
6 Months
+57.47%
Year to Date
+18.27%
1 Year
+21.86%
View Detailed Chart
TradingKey Stock Score of 10X Genomics Inc
Currency: USD Updated: 2026-01-08Key Insights
10X Genomics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 17.27.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
10X Genomics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
10X Genomics Inc Highlights
StrengthsRisks
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.28% year-on-year.
Undervalued
The company’s latest PE is -30.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 125.94M shares, decreasing 11.00% quarter-over-quarter.
Held by HOTCHKIS & WILEY
Star Investor HOTCHKIS & WILEY holds 2.42K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.35.
Analyst Rating
Based on
18
analysts
Hold
Current Rating
17.267
Target Price
-5.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
10X Genomics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
10X Genomics Inc Info
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Ticker SymbolTXG
Company10X Genomics Inc
CEOSaxonov (Serge Wilson)
Websitehttps://www.10xgenomics.com/
FAQs
What is the current price of 10X Genomics Inc (TXG)?
The current price of 10X Genomics Inc (TXG) is 19.290.
What is the symbol of 10X Genomics Inc?
The ticker symbol of 10X Genomics Inc is TXG.
What is the 52-week high of 10X Genomics Inc?
The 52-week high of 10X Genomics Inc is 20.340.
What is the 52-week low of 10X Genomics Inc?
The 52-week low of 10X Genomics Inc is 6.780.
What is the market capitalization of 10X Genomics Inc?
The market capitalization of 10X Genomics Inc is 2.44B.
What is the net income of 10X Genomics Inc?
The net income of 10X Genomics Inc is -182.63M.
Is 10X Genomics Inc (TXG) currently rated as Buy, Hold, or Sell?
According to analysts, 10X Genomics Inc (TXG) has an overall rating of Hold, with a price target of 17.267.
What is the Earnings Per Share (EPS TTM) of 10X Genomics Inc (TXG)?
The Earnings Per Share (EPS TTM) of 10X Genomics Inc (TXG) is -0.624.
Related Instruments
+1.42%
-1.78%
-0.72%
-1.21%
-0.28%
-0.27%
-0.16%
-1.09%
+1.78%
+0.98%
+2.19%
+1.71%
-1.41%
+1.20%
-0.30%
-0.27%
-1.41%
+2.80%
-0.52%
+0.77%
